Background and Data Delay Resolution of Real-Time Clinical Trials (RTCT)

The U.S. Food and Drug Administration (FDA) has officially announced the launch of a pilot program for Real-Time Clinical Trials (RTCT) to innovate clinical trial processes. Conventional clinical trials have been criticized for causing administrative 'dead time' of several months between data collection and submission to regulatory agencies, which has been a major obstacle to accelerating new drug development. To overcome this inefficiency, the FDA has established a new operational framework that leverages cloud and digital health technologies to track clinical patient data and safety signals in real-time. This initiative is significant because it drastically shortens the development period of innovative drugs without relaxing regulatory standards, thereby providing patients with faster access to treatment.

Demonstration of Innovative Pipelines from AstraZeneca and Amgen

To verify the technical feasibility of this pilot program, major clinical pipelines from global pharmaceutical companies AstraZeneca and Amgen have been selected as demonstration cases. AstraZeneca is conducting the 'TrAVeRse' study, a Phase 2 clinical trial evaluating the efficacy of a triple combination therapy with BTK inhibitor Calquence (acalabrutinib) for patients with mantle cell lymphoma (MCL) who have not received prior treatment, and is transmitting real-time data. Amgen is also providing data from the 'STREAM-SCLC' study, a Phase 1b clinical trial targeting patients with limited-stage small cell lung cancer (SCLC) with Imdelltra (tarlatamab), a DLL3 and CD3-targeting bispecific T-cell engager (BiTE) therapy. The real-time sharing of clinical data from these two innovative drugs has successfully demonstrated the possibility of real-time safety monitoring even in complex oncology clinical trials.

Paradigm Health's Technology Platform and Real-Time Data Collection

The key driver enabling real-time data transmission and verification is the collaboration with Paradigm Health, a digital health technology startup. Paradigm Health's 'Study Conduct Platform' and 'SPIRE (Scalable Platform for Integrated Research and Evidence)' technologies directly extract data from electronic health records (EHRs) in healthcare institutions and perform automated analysis. This eliminates manual data entry, minimizes errors, and creates an environment where regulatory agencies can immediately verify the integrity of the data. As a result, the FDA has successfully verified the technical signals derived from AstraZeneca's clinical trial, clearly demonstrating the feasibility of real-time regulatory monitoring.

Reduction in Clinical Costs and Acceleration of Personalized Medicine

In the long term, the establishment of a real-time clinical trial system will significantly reduce the monitoring and data management costs, which account for a considerable portion of the total clinical trial costs for pharmaceutical companies. While there are challenges to be addressed, such as the need for enhanced frameworks for data security and privacy protection, the combination of artificial intelligence (AI)-based analysis and digital biomarker technology will accelerate the development of personalized treatments. Clinical trial participants will also benefit from reduced burdens associated with frequent hospital visits and immediate medical care in the event of adverse events, leading to improved clinical trial satisfaction and safety. The FDA plans to complete the Request for Information (RFI) process by June 29, 2026, and will finalize the selection of pilot participants in August of this year, before launching a full-scale rollout of the system.